Olivier Steichen
Overview
Explore the profile of Olivier Steichen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monchausse T, Launay T, Rossignol L, Ait El Belghiti F, Brisse S, Guiso N, et al.
Vaccine
. 2025 Feb;
51:126862.
PMID: 39952119
The French national surveillance of pertussis consists of several units, including general practitioners (GPs). Here, we report on the clinical characteristics of cases from January to December 2024 from primary...
2.
Wassermann E, Bachmeyer C, Lemaitre G, Bernaux M, Daniel C, Leblanc J, et al.
Rev Med Interne
. 2025 Feb;
PMID: 39922759
Objectives: Hospital-acquired infections (HAIs) during community disease outbreaks threaten vulnerable hospitalized patients. This study compares the outcomes of hospitalized patients who had COVID-19 as either a HAI or a community-acquired...
3.
Steichen O
Lancet Diabetes Endocrinol
. 2025 Jan;
13(2):80-81.
PMID: 39824203
No abstract available.
4.
Dawudi Y, Azoyan L, Bonjour M, Steichen O
Ann Hematol
. 2024 Dec;
103(12):5071-5083.
PMID: 39658700
Individuals with sickle cell disease (SCD) and sickle cell trait (SCT) face an increased risk of complications from COVID-19 due to their susceptibility to infections and venous thromboembolism. We selected...
5.
Tebeka S, Coste J, Makovski T, Alleaume C, Delpierre C, Gallay A, et al.
J Psychosom Res
. 2024 Oct;
187:111961.
PMID: 39454250
Objective: Depressive symptoms may overlap with those of long COVID. This cross-sectional study aims to compare the prevalence of depressive symptoms among individuals infected with SARS-CoV-2 with versus without long...
6.
Etienne C, Vilcu A, Finet F, Chawki S, Blanchon T, Steichen O, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1184.
PMID: 39434000
Background: Immunosuppressive therapies are associated with a risk of infections. Nevertheless, their incidence in this population remains unclear. This study aims to determine the incidence of serious respiratory tract infections...
7.
Rech J, Postel-Vinay N, Vercamer V, de Villele P, Steichen O
J Hypertens
. 2024 Sep;
43(1):90-97.
PMID: 39315540
Objective: Connected blood pressure (BP) monitors provide reliable data when used properly. Our objective was to analyse the engagement of real-world users with self-measurements. Methods: We included adult first-time users...
8.
Coste J, Delpierre C, Richard J, Alleaume C, Gallay A, Tebeka S, et al.
Clin Microbiol Infect
. 2024 Mar;
30(7):924-929.
PMID: 38527615
Objectives: Long COVID has been recognized since early 2020, but its definition is not unanimous, which complicates epidemiological assessments. This study estimated the prevalence of long COVID based on several...
9.
de Berny Q, Saint-Jacques C, Santin A, Mattioni S, Steichen O, Chieze R, et al.
Am J Physiol Renal Physiol
. 2023 Dec;
326(2):F278-F284.
PMID: 38059298
The urine concentration impairment responsible for hyposthenuria in sickle cell nephropathy is currently thought to be a consequence of renal medulla lesions, which lead to nephrogenic diabetes insipidus. The objective...
10.
Gosselin L, Vilcu A, Souty C, Steichen O, Launay T, Conte C, et al.
Eur J Clin Pharmacol
. 2023 May;
79(7):937-945.
PMID: 37184597
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and P-glycoprotein inhibitors such as amiodarone, verapamil and diltiazem. We aimed to estimate the prevalence of exposure to this drug-drug...